

## CURRICULUM VITAE

**NAME:** **Li** **Lang**  
Last First Middle

---

### EDUCATION:

#### GRADUATE

University of New Mexico	M.A. (Statistics)	August 1994 – June 1996
University of Michigan	Ph.D. (Biostatistics)	August 1996 – August 2001

#### UNDERGRADUATE

Wuhan University of Technology, P.R. China,	B.A. (MechE)	August 1988 – July 1992
---	--------------	-------------------------

### FURTHER EDUCATION:

#### APPOINTMENTS:

Department of Mathematics and Statistics University of New Mexico	08/1994 – 12/1996	Teaching Assistant,
Department of Biostatistics, University of Michigan	09/1996 – 12/1996	Teaching Assistant
Comprehensive Cancer Center, University of Michigan	01/1997 – 08/2001	Research Assistant
Division of Biostatistics, Department of Medicine School of Medicine, Indiana University	08/2001 – 07/2005	Assistant Professor
Regenstrief Research Institute	08/2001 – now	Research Scientist
Indiana University Simon Cancer Center	08/2003 – 07/2017	Full Member
Division of Clinical Pharmacology, Department of Medicine School of Medicine, Indiana University	08/2003 – 07/2017	Assistant Professor
Center for Computational Biology and Bioinformatics School of Medicine, Indiana University	12/2003 – 07/2017	Full Member
Division of Biostatistics, Department of Medicine School of Medicine, Indiana University	08/2005 – 07/2010	Associate Professor
Bioinformatics Core School of Medicine, Indiana University	04/2007 – 01/2010	Director
Informatics and Biostatistics Program Indiana Clinical Translational Science Institute	08/2008 – 07/2017	Associate Director
Department of Medical and Molecular Genetics School of Medicine, Indiana University	07/2010 – 06/2014	Associate Professor
Center for Computational Biology and Bioinformatics, School of Medicine, Indiana University	10/2010 – 02/2013	Associate Director

Indiana Institute of Personalized Medicine School of Medicine, Indiana University	01/2011 – 07/2017	Associate Director
Center for Computational Biology and Bioinformatics, School of Medicine, Indiana University	02/2013 – 07/2017	Director
Department of Medical and Molecular Genetics School of Medicine, Indiana University	06/2014 – 07/2017	Professor
School of Medicine, Indiana University	01/2015 – 07/2017	T. K. Li Endowed Chair of Medical Research
Indiana University Simon Cancer Center	07/2015 – 07/2017	Leadership Council
Precision Health Grant Challenge School of Medicine, Indiana University	04/2015 – 07/2017	Steering Committee
Department of Biomedical Informatics College of Medicine, The Ohio State University	07/2017- now	Chair and Professor

#### **LICENSURE, CERTIFICATION, SPECIALTY BOARD STATUS**

##### **PROFESSIONAL ORGANIZATION MEMBERSHIPS:**

Member of the American Statistical Association	06/1994 – now
Member of the International Biometric Society, Eastern North American Region	06/1994 – now
Member of the International Society of Bioinformatics	06/2002 – now
Member of the Association of Clinical Pharmacology and Therapeutics	01/2001 – now
Member of the International Society of Computational Biology	06/2004- now
Scientific Program Committee American Society of Clinical Pharmacology and Therapeutics	06/2010 – 06/2013
Biostatistics and Bioinformatics Advisory Committee and Genomics Study Review Committee of the Pharmacogenetics Research Network	09/2010 – now
Associate Editor of Clinical Pharmacology and Therapeutics Pharmacometrics and System Pharmacology	03/2013 – now
Strategic Planning Committee American Society of Clinical Pharmacology and Therapeutics	04/2014 – 12/2015
Associate Editor of IEEE Transaction Bioinformatics and Computational Biology	11/2014 - now

##### **PROFESSIONAL HONORS AND AWARDS:**

###### **TEACHING**

###### **RESEARCH**

Travel Award (2001 ENAR Paper Competition)	2001
Travel Award (2001 JSM Paper Competition Biopharmaceutical Section)	2001

SERVICE

OVERALL/OTHER

**PROFESSIONAL DEVELOPMENT:** List courses, workshops or training programs attended to enhance your performance in any area of academic work.

Course/Workshop Title	Provider	Date
-----------------------	----------	------

**LIBRARIAN PERFORMANCE:**

**TEACHING:**

TEACHING ASSIGNMENTS:

GRADUATE

Course #	Short Title	Format	Role	Term	Enrollment
BIOS 651	Biostatistics	lecture	Course Director	2001-2013	90
CSCI 548	Intro. to Bioinfo.	Lecture	Lecturer	2002	30
I532	Bioinfo. Seminar	Lecture	Lecturer	2002	6
BME 695	Adv. Biomolecular Engineering	Lecture	Lecturer	2002	20
BIOS 685 (new course)	Nonlinear Mixed Effect Model	Lecture	Course Director	2009	10
G848	Intro. to Bioinfo.	Lecture	Lecturer	2011-2013	20

POSTGRADUATE

Clinical Pharmacology Didactic Training	Lecture	Lecturer	2001-2013	82
---	---------	----------	-----------	----

CONTINUING EDUCATION: N/A

**MENTORING:** List mentoring activities that pertain to your discipline such as thesis or advisory committees, students on research rotations, postdoctoral fellows and visiting scholars, advisor to graduating students, mentor for peer and self-assessment review, faculty mentoring committees. Name the individual, identify your role and provide inclusive dates.

Individual	Role	Inclusive Dates
<i>Post-Docs</i>		
Seongho Kim (Biostatistics)	Mentor	2006-2008
Sara K. Quinney (Bioinformatics)	Mentor	2007-2009
Zuoyi Zhang (Biostatistics)	Mentor	2011-2013
Raphael Mourad (Bioinformatics)	Mentor	2011-2012
Arindom Chakraborty (Bioinformatics)	Mentor	2012-2014
Lijun Cheng (Bioinformatics)	Mentor	2014-2016
Bhagya K. Wijayawardena (Bioinformatics)	Mentor	2015 - now
Garrett Kinnebrew (Bioinformatics)	Mentor	2016 – now
Pengyue Zhang (Biostatistics)	Mentor	2016 – now
Lei Wang	Mentor	2016 – now
<i>Ph.D. Students</i>		
Jihao Zhou (Biostatistics)	Thesis Committee, Chair	2002-2006
Zhiping Wang (Bioinformatics)	Thesis Committee, co-Chair	2004-2012
Han Xu (Pharmacology and Toxicology)	Thesis Committee, co-Chair	2008-2014
Pengyue Zhang (Biostatistics)	Thesis Committee, Chair	2009-2016
Santosh Philips (Bioinformatics)	Thesis Committee, Chair	2009-2016

Claire Li (Medical and Molecular Genetics)	Thesis Committee, Chair	2009-2015
Claire Xu (Pharmacology and Toxicology)	Thesis Committee	2008-2013
Yang-yang Hao (Medical and Molecular Genetics)	Thesis Committee	2010-2015
Hengyi Wu (Bioinformatics)	Thesis Committee, Chair	2009-now
ChienWei Chiang (Bioinformatics)	Thesis Committee, Chair	2009-now
Aida Yazdanparast (Bioinformatics)	Thesis Committee, Chair	2015-now
Yang Huo (Bioinformatics)	Thesis Committee, Chair	2015-now
Enze Liu (Bioinformatics)	Thesis Committee, Chair	2015-now
Muntasir Zitu (Bioinformatics)	Thesis Committee, Chair	2016-now
Samar Binkheder (Health Informatics)	Thesis Committee, Chair	2016 – now
Xueying Wang (Bioinformatics)	Thesis Committee, Chair	2016 – now
Fan Yang (Bioinformatics)	Thesis Committee, Chair	2016 – now

**Master Students**

Timothy Breen (bioinformatics)	Thesis Committee, Chair	2002-2005
Robert Miller (bioinformatics)	Thesis Committee, Chair	2003-2005
Abhinita Subhadashini (bioinformatics)	Thesis Committee, Chair	2008-2012
Shreyas D. Karnik (bioinformatics)	Thesis Committee, Chair	2008-2012
Sriharsha Guntupalli (bioinformatics)	Thesis Committee, Chair	2009-2013
Hrishikesh A. Lokhande (bioinformatics)	Thesis Committee, Chair	2009-2013
Prasad K. Lakshmi (bioinformatics)	Thesis Committee, Chair	2009-2013
Pondugala R. Lakshmi (bioinformatics)	Thesis Committee, Chair	2009-2013
Scott P. Alexander (bioinformatics)	Thesis Committee, Chair	2009-2013
Shevate Swapnil (bioinformatics)	Thesis Committee, Chair	2009-2013

**TEACHING ADMINISTRATION AND CURRICULUM DEVELOPMENT:** N/A

**GRANTS/FELLOWSHIPS IN TEACHING:** N/A

**RESEARCH/CREATIVE ACTIVITY:**

**GRANTS/FELLOWSHIPS IN RESEARCH:** Organize grants to differentiate active from pending/under review. Include your history of past grant support. If a record of effort to obtain funding is expected in your discipline and/or rank, include proposal submitted but not funded.

**ACTIVE RESEARCH GRANTS/FELLOWSHIPS**

Title	Granting Agency	Role	Effort	Total Cost (FY)	Duration
Drug Interaction Involving Anti-diabetic Agents (RO1)	NIDDK	Multi-PI	10%	\$583,142	09/2014–08/2018
A Translational Biomedical Informatics Framework in the Drug Interaction (RO1)	NIGMS	PI	15%	\$469,971	07/2014-06/2018
Evidence-based Drug-Interaction Discovery: In-Vivo, In-Vitro and Clinical (RO1)	NLM	Contact-PI	20%	\$397,274	07/2014-06/2018
Clinical Importance of Drug-Drug Interactions	NIA	multiple-PI	10%	\$646,786	05/2017-04/2022
Mining Drug-Drug Interaction Induced Adverse Effects from Health Record Databases	NSF	PI	10%	\$321,233	02/2016-01/2020

Walther Bioinformatics-Molecular Genomics/Genetics Joint IU-Purdue Initiative	Walther Cancer Foundation	co-PI	10%	\$1,000,000	07/2015-06/2017
High-dimensional Drug Interaction (RO1)	NIGMS	co-I	15%	\$332,088	11/2016-10/2019
Embedding Pharmacogenotyping in an Integrated Health System (UO1)	NHGRI	co-I	5%	\$1,050,414	03/2014-02/2018
Indiana University Center Pediatric Pharmacology and Precision Medicine (U54)	NICHHD	co-I	5%	\$823,068	07/2016-06/2021
Developmental and Hyper-Active RAS Tumor Spore (U54)	NCI	co-I	5%	\$2,162,000	12/2015-11/2020
An Integrative Approach to Identify Causal Epigenetic Markers for Breast Cancer (RO1)	NCI	co-I	5%	\$493,991	05/2015-06/2019
Target FASN for Breast Cancer Treatment by Repositioning PPIs	DOD	co-I	5%	\$234,214	05/2016-0/6/2020

#### COMPLETED RESEARCH GRANTS/FELLOWSHIPS

Title	Granting Agency	Role	Effort	Amount	Dates
Bayesian Tools for Drug Interaction Research (RO1)	NIGMS	PI	30%	\$225,000/yr	2006-2011
Pharmacogenetics of Aromatase Inhibitor (P01)	NIGMS	Bioinfo. Director	15%	\$1,773,000/yr	2005-2011
System Cancer Epigenomics Integrative Cancer Biology Program (P50)	NCI	Project co-PI	10%	\$1,500,000/yr	2010-2015
GWAS of the Bevcizumab Breast Cancer Trial	KOMEN	Bioinfo. Director	5%	\$1,200,000/yr	2009-2014
Indiana PREGMED (P50)	NICHHD	co-I	5%	\$649,991/yr	2009-2014
Pharmacogenetic Determinants of Vincristine Toxicity and Response (RO1)	NICHHD	co-I	5%	\$2,881,487	2011-2015
Genetic predictors of taxane induced peripheral neuropathy	Conquer Cancer Foundation	co-I	5%	\$139,500/yr	2011-2014

#### PENDING RESEARCH GRANTS

Title	Granting Agency	Role	Effort	Total Cost (FY)	Dates
Systems Biology of Metastasis to the Liver (U54)	NCI	contact-PI	25%	\$2,032,325	2017-2022
Maximizing the Utility of Precision Medicine at the Population Level Using the Electronic Health Record Data (RO1)	NHLBI	multiple-PI	20%	\$498,423	2017-2020

### INVITED PRESENTATIONS – RESEARCH

#### LOCAL

Title	Organization	Date
A New Detection Algorithms for the Affymetrix Microarray	IU Computer Science	04/2003
Population Pharmacokinetic Model with Time-Varying Covariates	Eli Lilly, Inc. Indianapolis	09/2003
Challenges and Prospects in Physiologically Based Models for Drug-Drug Interaction Prediction	Department of Statistics IUPUI	02/2006
Translational Drug Interaction Research	IU School of Informatics Bloomington	04/2012
Translational Drug Interaction Research	IU School of Informatics Bloomington	10/2012
Translational Spectrum of Biomedical Informatics Research	IU School of Medicine	03/2013
Translational Spectrum of Biomedical Informatics Research	IU School of Informatics Indianapolis	03/2013

#### REGIONAL

Title	Organization	Date
An Up and Down Directed Clustering Algorithm for the Temporal Gene Expression	American Statistical Association Central Indiana Chapter	09/2003
Epigenetic Hypothesis Test for DNA Methylation and Histone Acetylation in a Triple-Array System	Statistics Department, Purdue	09/2005
Challenges and Prospects in Physiologically Based Models for Drug-Drug Interaction Prediction	Medical Science Indiana University, Bloomington	02/2006
Translational Drug Interaction Research	Statistics Department, Purdue	09/2012
Translational Drug Interaction Research	Statistics Department, Notre Dame	04/2012

#### NATIONAL

Title	Organization	Date
-------	--------------	------

Population Pharmacokinetic Model with Time-Varying Covariates measured with or without error	Department of Statistics University of Illinois, Urbana-Champaign	10/2002
The Application of Variable Selection and False Discovery Rate	Pharmacogenetic Research Network Annual Meeting Memphis, TN	04/2003
An Up and Down Directed Clustering Algorithm for the Temporal Gene Expression	Department of Biostatistics, University of Pittsburgh	10/2003
Population Pharmacokinetic Model with Time-Varying Covariates	Department of Biostatistics Ohio State University	11/2003
Challenges and Prospects in Physiologically Based Models for Drug-Drug Interaction Prediction	Biostatistics Georgetown University, Washington, DC	02/2006
Challenges and Prospects in Physiologically Based Models for Drug-Drug Interaction Prediction	Biostatistics University of Pennsylvania Philadelphia, PA	04/2006
Epigenetics in Cancer Research	Integrative Cancer Biology Workshop Nashville, TN	05/2006
Challenges and Prospects in Physiologically Based Models for Drug-Drug Interaction Prediction	International Statistical Conference Storrs, CT	06/2007
Epigenetics in Cancer Research	Western North American Region of the International Biometric Society Flagstaff, AZ	06/2007
An Integrated Pharmacogenetics Drug-Interaction Personalized Medicine	American Society of Clinical Pharmacology and Therapeutics Orlando, FL.	03/2008
An Integrated Pharmacogenetics Drug-Interaction Personalized Medicine	Pharmacogenomics Research Network Mayo Clinics, Rochester, MN	09/2009
Pharmacokinetics PK Parameter Based Text Mining	Pacific Symposium of Biocomputing	01/2009
An Integrated Pharmacogenetics Drug-Interaction Personalized Medicine	Department of Biostatistics Brown University Providence, RI	02/2010
An Integrated Pharmacogenetics Drug-Interaction Personalized Medicine	International Chinese Association of Statistics Indianapolis, IN	04/2010
An Integrated Pharmacogenetics Drug-Interaction Personalized Medicine	Department of Bioinformatics University of Kentucky, Lexington, KY	08/2010

An Integrated Pharmacogenetics Drug-Interaction Personalized Medicine	Statistical and Applied Mathematical Science Institute, Durham, NC	07/2010
Translational Bioinformatics and Drug-Interaction	American Conference on Pharmacometrics San Diego, CA	08/2011
Translational Bioinformatics and Drug-Interaction	Pacific Coast Statisticians and Pharmacometricians Innovation Conference Cal Poly, San Luis Obispo, CA	09/2012
Drug Interaction	American Society of Clinical Pharmacology and Therapeutics Indianapolis, IN	03/2013
Drug Interaction	Eastern North American Region of the International Biometric Society Orlando, FL	03/2013
Drug Interaction	Arizona State University, Pheonix, AZ.	09/2013
Drug Interaction	University of Pennsylvania Philadelphia, PA.	09/2013
Drug Interaction	University of Texas South Western, TX.	11/2013
Translational Bioinformatics and Drug Interaction	University of Texas Houston, TX.	4/2014
Translational Biomedical Informatics and drug Interaction	Yale University New Haven, CT	3/2015
Precision Medicine	Purdue University West Lafayette, IN	4/2015
Translational Biomedical Informatics Research in Drug Interaction	University of North Carolina at Chapel Hill	9/2015
Translational Biomedical Informatics Research in Drug Interaction	American Conference of Pharmacometrics	10/2015
Translational Biomedical Informatics Research in Drug Interaction	American Association of Pharmaceutical Science Annual Meeting	11/2015
<b>INTERNATIONAL</b>		
Title	Organization	Date
Translational Spectrum of Biomedical Informatics Research	Indian-US Bioinformatics Conference Calicut, India	6/2011
Translational Spectrum of Biomedical Informatics Research	Academy of Biological Science Shanghai, China	10/2011
Translational Spectrum of Biomedical	Jiaotong University School of Medicine	06/2012



Informatics Research

Shanghai, China

**SERVICE:**

Distinguish between service to the University and service to your professional discipline. If a service activity spans academic levels (i.e. Department, School, Campus, University) list it once. Identify your role in leadership (i.e. member, co-chair, chair).

**UNIVERSITY SERVICE:**

**DEPARTMENT**

Activity	Role	Inclusive Dates
Faculty Recruiting Committee Department of Biostatistics	Committee Member	06/2002 – 06/2006
Tenure and Promotion Committee Department of Medical and Molecular Genetics	Committee Member	09/2011 – 06/2013

**SCHOOL**

Activity	Role	Inclusive Dates
Indiana CTSI Informatics and Biostatistics Program	Associate Director in Informatics	08/2008 – now
Indiana CTSI Biobank	Biomedical Informatics Subcommittee Chair	09/2009 – 12/2012
Indiana University Simon Cancer Center	Leadership Council	09/2015 - now
Precision Health Grant Challenge School of Medicine Indiana University	Steering Committee Informatics Component Leader	04/2015 - now

**CAMPUS**

Activity	Role	Inclusive Dates
----------	------	-----------------

**UNIVERSITY**

Activity	Role	Inclusive Dates
IRB-5	Committee Member Subcommittee Chair	06/2003 – 03/2013
CTSI Bioinformatics Core	Director	09/2008 – 12/2012
Indiana Institute of Personalized Medicine	Associate Director	01/2011 – now
Center for Computational Biology and Bioinformatics	Director	02/2013 – now

**PROFESSIONAL SERVICE:**

**LOCAL**

Organization	Activity	Inclusive Dates
--------------	----------	-----------------

**REGIONAL**

Organization	Activity	Inclusive Dates
Vice-president of the central Indiana	Monthly meeting	2002-2003

Chapter of the American Statistical Association

President of the central Indiana Chapter of the American Statistical Association	Monthly meeting	2003-2004
--	-----------------	-----------

NATIONAL Organization	Activity	Inclusive Dates
-----------------------	----------	-----------------

NIH RC2 Review Study Section	Reviewer	02/2010
------------------------------	----------	---------

NIH RC4 Review Study Section	Reviewer	04/2010
------------------------------	----------	---------

National Centers of Bio-computing Study Section	Reviewer	06/2010
---	----------	---------

NCI Technical Review Panel	Reviewer	10/2010
----------------------------	----------	---------

NHLBI Program Project Review Panel	Reviewer	04/2010
------------------------------------	----------	---------

NIH System Biology Program Project Review Panel	Reviewer	03/2014
---	----------	---------

NIH Biomedical and Health Informatics Study Section	Reviewer	11/2014
---	----------	---------

NIH Special Panel for Center of Excellence for Natural Product Drug Interaction Research (U54)	Reviewer	03/2015
--	----------	---------

NIH Academic Research Enhancement Award, Study Section ZRG1 HDM-W	Reviewer	11/2015
---	----------	---------

NIH COBRE Special Emphasis Panel	Reviewer	06/2016
----------------------------------	----------	---------

American Society of Clinical Pharmacology and Therapeutics	Scientific Program Committee	2009-2015
--	------------------------------	-----------

INTERNATIONAL Organization Pharmacometrics and System Pharmacology	Activity Associate Editor	Inclusive Dates 03/2013 - now
--	---------------------------	-------------------------------

IEEE Transaction Bioinformatics And Computational Biology	Associate Editor	11/2014 - now
---	------------------	---------------

**PATIENT CARE/CLINICAL SERVICE:** N/A

**GRANTS/FELLOWSHIPS IN SERVICE:**

**PUBLICATIONS:**

TEACHING

RESEARCH/CREATIVE ACTIVITY

## Refereed

1. Vladimir K and **Li L**. A new symmetry test for multivariate distribution. *Journal of Multivariate Analysis*, 1998, 65: 228-44.
2. Smith DC, Redman BG, Flaherty LE, **Li L**, Strawderman M, and Pienta KJ. A phase II trial of oral diethylstilbesterol as a second line hormonal agent in advanced prostate cancer. *Urology*, 1998, 52: 257-260.
3. McKeever PE, Junck L, Strawderman M, Blaivas M, Tkaczyk A, Cates MA, Yan M and **Li L**. Proliferation Index is related to patient age in Glioblastoma. *Neurology*, 2001, 56: 1216-1218.
4. Chaib H, Rubin MA, Mucci NR, **Li L**, Taylor MJ, Day ML, Rhim J, and Macoska J. Activated in Prostate Cancer: A PDZ Domain-Containing Protein Highly Expressed in Human Primary Prostate Tumors. *Cancer Research*, 2001, 61: 2390-2394.
5. Song J, Tata D, **Li L**, Taylor J, Bao S, and Miller DL. Combined shockwave and immuno-gene therapy of mouse melanoma and renal carcinoma tumors. *Ultrasound in Medicine and Biology*, 2002, 28: 957-964.
6. **Li L**, Brown M, Lee K. and Gupta S. Estimation and inference for a spline-enhanced nonlinear population pharmacokinetic model. *Biometrics*, 2002, 58: 601-611.
7. Wang Z, Hall S D, Maya JF, **Li L**, Ashgar A, and Gorski CJ. Diabetes mellitus increases the in vivo activity of cytochrome P450 2e1 in human. *British Journal of Clinical Pharmacology*, 2002, 55: 77-85.
8. Desai M, **Li L**, Desta Z, Malik M, and Flockhart D. Variability of Heart Rate Correction Methods for the QT Interval: Potential for QT<sub>c</sub> Overestimation with a Low Dose of Haloperidol. *British Journal of Clinical Pharmacology*, 2003, 55: 511-517.
9. Desai M, Tanus-Santos J, **Li L**, Gorski JC, Arefayene M, Liu Y, Desta Z, and Flockhart D. Pharmacokinetics and QT interval pharmacodynamics of oral haloperidol in poor and extensive metabolizers of CYP2D6. *The Pharmacogenomic Journal*, 2003, 3: 105-113.
10. Zeng G, Hu, Z, Kinch MS, Pan C, Flockhart, Kao C, Gardner TA, Zhang S, **Li L**, Baldrige LA, Koch MO, Ulbright TM, Eble JN, and Cheng L. High level expression of EphA2 receptor tyrosine kinase in prostatic intraepithelial neoplasia. *American Journal of Pathology*, 2003, 163: 2271-6.
11. **Li L**, Huang J, Sun S, Shen J, Unverzagt F, Gao S, Hendrie H, Hall K, and Hui S. Selecting Pre-Screening Items for EARLY INTERVENTION Trials of Dementia – A Case Study. *Statistics in Medicine*, 2004, 23: 271-283.
12. Pan C, Kinch MS, Sweeney CJ, **Li L**, Zhang S, Baldrige LA, Koch MO, Ulbright TM, Eble JN, and Cheng K. PC cell-derived growth factor (PCDGF, epithelin/granulin precursor) Expression Correlates with Progression of Prostate Cancer. *Clinical Cancer Research*, 2004, 10: 1333-1337.
13. Cheng L, Pan C, Zhang JT, Zhang S, Kinch MS, **Li L**, Baldrige LA, Wade C, Hu Z, Koch MO, Ulbright TM, and Eble JN. Loss of 14-3-3s in prostate cancer and its precursors. *Clinical Cancer Research*, 2004, 10: 3064-3068.
14. **Li L**, Lin X, Brown MB, Gupta S. and Lee KH. A population pharmacokinetic model with time-dependent covariates measured with errors. *Biometrics*, 2004, 60: 451-460.

15. **Li L**, Desai M, Desta Z, and Flockhart D. QT analysis: a complex answer to a 'simple' problem. *Statistics in Medicine*, 2004, 23: 2625-2643.
16. Arora R, Koch MO, Eble JN, Ulbright TM, **Li L** and Chen L. Heterogeneity of Gleason Grade in Multifocal Adenocarcinoma of the Prostate. *Cancer* 2004, 100: 2362-2366.
17. Hong H, Kao C, Jeng MH, Eble JN, Koch MO, Gardner TA, Zhang S, **Li L**, Pan C, Hu Z, MacLennan GT, and Cheng L. Aberrant expression of CARM1, a transcriptional coactivator of androgen receptor, in the development of prostate cancer and androgen-independent status. *Cancer*, 2004, 101: 83-89.
18. Sweeney C, **Li L**, Shanmugam R, Bhat-Nakshatri P, Jayaprakasan V, Baldrige LA, Gardner T, Smith M, Nakshatri H, and Cheng L. Nuclear Factor Kappa B is constitutively activated in prostate cancer *in vitro* and is over-expressed in prostatic intra-epithelial neoplasia and adenocarcinoma of the prostate. *Clinical Cancer Research*, 2004, 10: 5501-5507.
19. Chen J, Sivachenkoand A, and **Li L**. High-throughput Protein Interactome Data: Minalbe or Not?, *Proceedings of the 4th ACM SIGKDD Workshop on Data Mining in Bioinformatics at the International Conference on Knowledge Discovery and Data Mining*, Seattle, WA, 2004, p18-23.
20. Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee J, Skaar T, Storniolo AM, **Li L**, Araba A, Blanchard R, Nguyen A, Ullmer L, Hayden J, Lemler S, Weinshilboum RM, Rae JM, Hayes DF, and Flockhart DA. Effects of CYP2D6 genotype and antidepressants on tamoxifen metabolism during adjuvant breast cancer treatment. *Journal of National Cancer Institute*, 2005, 97: 30-39.
21. Ho H, Pinto A, Hall SD, Flockhart DA, **Li L**, Skaar T, Cadman P, O'Connor DT, Wagner U, Fineberg N, and Weinberger MH. The association between the CYP3A5 genotype and blood pressure. *Hypertension*, 2005, 45: 294-298.
22. **Li L**, Shi H, Yiannoutsos C, Huang Tim, and Nephew K. Epigenetic hypothesis tests for methylation and acetylation in a triple microarray system. *Journal of Computational Biology*, 2005, 12: 370-390.
23. Adigun AQ, Pinto AG, Flockhart DA, Gorski JC, **Li L**, Hall SD, and Chalasani N. Effect of Cirrhosis and liver transplantation on the gender difference in QT interval. *The American Journal of Cardiology*, 2005, 95: 691- 694.
24. Borges S, **Li L**, Hamman MA, Jones DR, Hall SD, and Gorski C. Dextromethorphan to dextrophan urinary metabolic ratio does not reflect dextromethorphan oral clearance. *Drug Metabolism and Disposition*, 2005, 33: 1052-1055.
25. Rae J, Goetz M, Hayes D, **Li L**, Storniolo A, Stearns V, and Flockhart D. Letter to the Editor. *Breast Cancer Research*, 2005, 29: 7.
26. Shen C, **Li L**, and Chen J. Discover True association rates in multi-protein complex proteomics data sets. *Proceedings of the IEEE Computational Systems Biology Bioinformatics Conference*, Stanford University, Stanford, CA, published by IEEE Computer Society Press, 2005, 1: 167-174.
27. **Li L**. Statistical methods in bioinformatics – A review. *Briefings in Bioinformatics*, 2005, 6: 412.
28. Cibull TL, Jones TD, **Li L**, Eble JN, Baldrige LA, Malott SR, Luo Y, and Cheng L. Overexpression of PIM-1 during progression of prostatic adenocarcinoma. *Journal of Clinical Pathology*, 2006, 59: 285-288.
29. Marraffa JM, **Li L**, Ong G, and Lehman DF. Profound metoprolol induced bradycardia precipitated by Darvocet. *Clinical Pharmacology and Therapeutics*, 2006, 79: 282-286.

30. Schneider BP, Skaar T, Sledge GW, Badve S, **Li L**, and Flockhart DA. Analysis of angiogenesis genes from paraffin-embedded breast tumor and lymph nodes. *Breast Cancer Research and Treatment* 2006, 96: 209-215.
31. **Li L**, Hall S, and Desai M. QT analysis. *Encyclopedia of Biopharmaceutical Statistics*, 2006, Marcel Dekker.
32. Sanda C, Weitzel P, Tsukahara T, Schaley J, Edenberg H, Stephen M, McClintick J, Blatt L, **Li L**, Brodsky L, and Taylor M. Differential gene induction by type I and II interferons and their combination. *Journal of Interferon and Cytokine Research*, 2006, 26: 462-472.
33. Srirangam A, Mitra R, Wang M, Gorski C, Badve S, Baldrige LA, Hamilton J, Hawes J, **Li L**, Orschell CM, Srour EF, Blum JS, Sledge WG, Nakshatri H, and Potter DA. Effect of HIV protease inhibitor ritonavir on Akt-regulated cell proliferation in breast cancer. *Clinical Cancer Research*, 2006, 12: 1883-1896.
34. Wei S, Balch C, Paik H, Kim Y, Baldwin R, Liyanarachchi S, **Li L**, Wang Z, Wan J, Davuluri R, Karlan B, Gifford G, Brown R, Kim S, Huang T, and Nephew K. Prognostic DNA methylation biomarkers in ovarian cancer. *Clinical Cancer Research*, 2006, 12: 2788-2794.
35. Borges-Gonzulas S, Desta Z, **Li L**, Skaar T, Ward B, Nguyen A, Jin Y, Storniolo M, Nikoloff M, Koch W, Hayes D, Stearns V, and Flockhart D. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. *Clinical Pharmacology and Therapeutics*, 2006, 80: 61-74.
36. Shen C, **Li L**, and Chen J. A statistical framework to discover true associations from multi-protein complex pull-down proteomics data sets. *Proteins: Structure, Function, and Bioinformatics*, 2006, 64: 436-443.
37. Lim Y, **Li L**, Desta D, Zhao Q, Rae J, Flockhart DA, and Skaar T. Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells. *Journal of Pharmacology and Experimental Therapeutics*, 2006, 318: 502-513.
38. **Li L**, Cheng AS L, Jin V, Paik HH, Fan M, Li X, Zhang W, Robarge J, Balch K, Davuluri RV, Kim S, Huang T, and Nephew K. A mixture model based discriminate analysis for identifying ordered transcription factor binding site pairs in gene promoters directly regulated by estrogen receptor- $\alpha$ . *Bioinformatics*, 2006, 22: 2210-2216.
39. Hahn NM, Marsh S, Fisher W, Langdon R, Zon R, Browning M, Johnson CS, Scott-Horton TJ, **Li L**, McLeod HL, and Sweeney CJ. A Hoosier oncology group randomized phase II study of docetaxel plus vinorelbine and docetaxel plus estramustine in combination for the treatment of hormone refractory prostate cancer with pharmacogenetic survival analysis. *Clinical Cancer Research*, 2006 12: 6094-6099.
40. Chen Q, Yang Y, **Li L**, and Zhang JT. The amino terminus of the human multidrug resistance transporter ABCC1 has a U-shaped folding with a gating function. *Journal of Biological Chemistry*, 2006, 281: 31152-31163.
41. Fan M, Yan PS, Hartman-Frey C, Chen L, Paik H, Abbosh P, Cheng AS L, **Li L**, Huang HMT, and Nephew K. Breast cancer cells with acquired resistance to 4-hydroxytamoxifen and fulvestrant display divergent gene expression and DNA methylation signatures. *Cancer Research*, 2006, 66: 11964-11966.

42. **Li L**, Yu M, Chin R, Lucksiri A, Flockhart D, and Hall S. Drug-drug interaction prediction: A Bayesian meta-analysis approach. *Statistics in Medicine*, 2007, 26: 3700 - 3721.
43. Khalili A, Potter D, Yan P, **Li L**, Gray J, Huang T, and Lin S. Gamma-Normal-Gamma Mixture Model for detecting differentially methylated loci in three cancer cell lines. *Cancer Informatics*, 2007, [http://la-press.com/journals.php?pa=toc&journal\\_id=10&folder\\_id=15](http://la-press.com/journals.php?pa=toc&journal_id=10&folder_id=15).
44. **Li L**, Hui S, Desta Z, Todd S, Nguyen A, and Flockhart D. Estimating a positive false discovery rate for variable selection in pharmacogenetic studies. *Journal of Pharmaceutical Statistics*, 2007, 17: 883-902.
45. **Li L** and Hui S. Positive false discovery rate estimate in step-wise variable selection. *Communication in Statistics – Simulation and Computation*. 2007, 32: 2.
46. Jones DR, Ekins S, **Li L**, and Hall SD. Computational approaches that predict metabolic intermediate complex formation with CYP3A4(+b<sub>5</sub>). *Drug Metabolism and Disposition*, 2007, 35(9):1466-1475.
47. Abbosh PH, Li X, **Li L**, Gardner TA, Kao C, and Nephew KP. A conditionally replicative, WNT/beta-catenin pathway-based adenovirus therapy for anaplastic thyroid cancer. *Cancer Gene Therapy*, 2007, 1-10.
48. Jin Y, Wang Y-H, Miao J, **Li L**, Kovacs RJ, Marunde R, Hamman MA, Phillips S, Halligoss J, and Hall SD. Cytochrome P450 3A5 Genotype is Associated with Verapamil Response in Healthy Subjects. *Journal of Pharmacology and Experimental Therapeutics*, 2007, 82: 579-585.
49. Desta Z, Saussele T, Ward B, Bliedernicht J, **Li L**, Klein K, Flockhart DA, Zanger MU. Impact of CYP2B6 polymorphism on efavirenz metabolism *in vitro*. *Pharmacogenomics*, 2007, 8: 547-558.
50. Robarge JD, **Li L**, Desta Z, Nguyen A, and Flockhart DA. Evaluating genetic nonmenclature of drug metabolizing enzyme. *Journal of Clinical Pharmacology and Therapeutics*, 2007, 82: 244-248.
51. **Li L**. Discussion on parameter estimation for differential equations: a generalized smoothing approach. *Journal of the Royal Statistical Society, Series B*, 2007, 69: 787-788.
52. Hahn N, Kelley M, Klaunig JE, Koch MO, **Li L**, and Sweeney CJ. Constitutional polymorphisms of prostate cancer: prognostic and diagnostic implications. *Future Oncology*, 2007, 665-682.
53. Humphrey TL, **Li L**, Li X, Janowicz DM, Fortney KR, Zhao Q, Li W, McClintick J, Katz BP, Wilks DS, Edenberg HJ, and Spinola SM. Dysregulated immune profiles in skin and dendritic cells are associated with increased host susceptibility to *Haemophilus ducreyi* infection in human volunteers. *Journal of Infection and Immunity*. 2007, 75: 5686-5697.
54. Ntukidem NI, Nguyen AT, Stearns V, Rehman M, Schott A, Skaar T, Jin Y, Blanche P, **Li L**, Lemler S, Hayden J, Krauss RM, Desta Z, Flockhart DA, and Hayes D. Estrogen receptor genotypes, menopausal status and the lipid effects of tamoxifen, *Journal of Clinical Pharmacology and Therapeutics*, 2008, 85: 702-710.
55. Wang G, Wang X, **Li L**, Nephew NP, Edenberg HJ, Zhou FC, and Liu Y. Identification of transcription factor and microRNA binding sites in responsible to fetal alcohol syndrome. *BMC Genomics*, 2008, 9(Suppl 1): S19.
56. Wang X, Wang G, Shen C, **Li L**, Edenberg HJ, Sanford J, and Liu Y. Using RNase sequence specificity to refine the identification of RNA-protein binding regions. *BMC Genomics*, 2008, 9 (Suppl 1): S17.

57. Shen C, Wang Z, Shanker G, Zhang X, and **Li L**. A Hierarchical Statistical Model to Assess the Confidence of Peptides and Proteins Inferred from Tandem Mass Spectrometry. *Bioinformatics*, 2008, 24: 202-208.
58. Feng W, Liu Y, Wu J, Nephew KP, Huang T, and **Li L**. A Poisson mixture model to identify changes in RNA polymerase II binding quantity using high-throughput sequencing technology. *BMC Genomics*, 2008, 9: s23.
59. Henry NL, Giles JT, Ang D, Mohan M, Dadabhoy D, Robarge J, Hayden J, Lemler S, Shahverdi K, Powers P, **Li L**, Flockhart D, Stearns V, Hayes DF, Storniolo AM, and Clauw DJ, Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. *Breast Cancer Research Treatment*, 2008, 111: 365-372.
60. Schneider BP, Radovich M, Sledge GW, Robarge JD, **Li L**, Storniolo AM, Lemler S, Nguyen AT, Hancock BA, Stout M, Skaar T, and Flockhart DA. Association of polymorphisms of angiogenesis genes with breast cancer. *Breast Cancer Research Treatment*, 2008, 111: 157-163.
61. Li M, Paik H, Balch C, Kim Y, **Li L**, Huang H-M T, Nephew PK, and Kim S. Enriched transcription factor binding sites in hypermethylated gene promoters in cancer cells. *Bioinformatics*, 2008, 15: 1745-1748.
62. Jin Y, Hayes DF, **Li L**, Robarge D, Skaar TC, Philips S, Nguyen A, Schott A, Hayden J, Lemler S, Storniolo AM, Flockhart DA, and Stearns V. Menopausal status and estrogen receptor genotypes influence hot flash frequency and composite score before and after tamoxifen therapy. *Journal of Clinical Oncology*, 2008, 26: 5849- 5854.
63. **Li L**, Yu M, Robarge J, Shen C, Jin Y, Borges-Gonzales S, Nguyen A, Skaar T, Desta Z, McLeod H, Sweeney CJ, and Flockhart D. A penalized mixture model approach in gene-gene and gene-environmental interactions for binary phenotypes. *Journal of Pharmaceutical Statistics*, 2008, 18: 1150-1177.
64. Yu M, Kim S, Wang Z, Hall S, and **Li L**. Drug-drug interaction prediction: A Bayesian meta-analysis approach. *Journal of Biopharmaceutical Statistics*, 2008, 18: 1063-1083.
65. Schneider B, Radovich M, Flockhart DA, Carpenter JS, **Li L**, Robarge JD, Storniolo AM, Hancock BA, Skaar TC, and Sledge GW. Exploratory study evaluating the association of polymorphisms of angiogenesis genes with hot flashes. *Breast Cancer Research and Treatment*, 2009, 116: 543-549.
66. Zhou J, Qin Z, Quinney SK, Kim S, Wang Z, Yu M, Chien JY, Lucksiri A, Hall DS, and **Li L**. A new probabilistic rule for drug-drug interaction prediction. *Journal of Pharmacokinetics and Pharmacodynamics*. 2009, 36: 1-18.
67. Srinivasan BS, Chen J, Cheng C, Conti D, Duan S, Fridley BL, Gu X, Haines JL, Jorgenson E, Kraja A, Lasky-Su J, **Li L**, Wang D, Rodin A, Province M, and Ritchie MD. Methods for analysis in pharmacogenomics: Lessons from the Pharmacogenetics Research Network (PGRN) Analysis Group. *Pharmacogenomics Journal*, 2009, 10: 243-251.
68. Onitilo AA, McCarty CA, Wilke RA, Glurich I, Engel JM, Flockhart DA, Nguyen A, **Li L**, Mi D, Skaar TC, and Jin Y. Estrogen receptor genotype is associated with risk of venous thromboembolism during tamoxifen therapy. *Breast Cancer Research and Treatment*, 2009, 115: 643-650.

69. Desta Z, Modak A, Nguyen PD, Lemler SM, Kurogi Y, Li L, and Flockhart DA. Rapid identification of the hepatic cytochrome P450 2C19 activity using a novel and noninvasive [<sup>13</sup>C] pantoprazole breath test. *Journal of Pharmacologic Experimental Therapeutics*, 2009, 329: 297-305.
70. Rae JM, Sikora MJ, Henry NL, Li L, Kim S, Oesterreich S, Skaar TC, Nguyen AT, Desta Z, Storniolo AM, Flockhart DA, Hayes DF, and Stearns V. Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients. *Pharmacogenomics*, 2009, 9: 258-264.
71. Henry NL, Rae JM, Li L, Azzouz F, Skaar TC, Desta Z, Sikora MJ, Philips S, Nguyen AT, Storniolo AM, Hayes DF, Flockhart DA, and Stearns V. Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort. *Breast Cancer Research Treatment*, 2009, 117(3):571-575.
72. Wang Z, Kim S, Quinney SK, Guo Y, Hall SD, Rocha LM, and Li L. Literature mining on pharmacokinetics numerical data: a feasibility study. *Journal of Biomedical Informatics*, 2009, 42: 725-735.
73. Miao J, Jin Y, Marunde RL, Kim S, Quinney S, Radovich M, Li L, and Hall SD. Association of genotypes of the CYP3A cluster with midazolam disposition *in vivo*. *Pharmacogenomics Journal*, 2009, 9: 319-326.
74. Haas DM, Hebert MF, Soldin OP, Flockhart DA, Madadi P, Nocon JJ, Chambers CD, Hankins, GD, Clark S, Wisner KL, Li L, Renbarger JL, and Learman LA. Pharmacotherapy and pregnancy: highlights from the Second International Conference for Individualized Pharmacotherapy in Pregnancy. *Clinical Translational Science*, 2009, 2:439-443.
75. Hommoud ZT, Badve S, Zhao Q, Li L, Saxena R, Thorat MA, Morimiya A, Rieger KM, and Kesler KA. Differential gene expression profiling of esophageal adenocarcinoma. *The Journal of Thoracic and Cardiovascular Surgery*, 2009, 137: 829-843.
76. Zhou J, Qin Z, Quinney SK, Kim S, Wang Z, Hall DS, and Li L. Equivalence Tests between Model based Drug-Drug Interaction Simulations and Published Drug-Drug Interaction. *Journal of Biopharmaceutical Statistics*. 2009, 19: 641-657.
77. Sweeney C, Li L, Shanmugam R, Bhat-Nakshatri P, Jayaprakasan V, Baldrige LA, Gardner T, Smith M, Nakshatri H, and Cheng L. Nuclear factor-kappaB is constitutively activated in prostate cancer *in vitro* and is overexpressed in prostatic intraepithelial neoplasia and adenocarcinoma of the prostate. *Clinical Cancer Research*, 2004, 10(16): 5501-5507.
78. Henry NL, Nguyen A, Azzouz F, Li L, Robarge J, Philips S, Cao D, Skaar TC, Rae JM, Storniolo AM, Flockhart DA, Hayes DF, and Stearns V. Lack of association between oestrogen receptor polymorphisms and change in bone mineral density with tamoxifen therapy. *British Journal of Cancer*, 2010, 102: 294-300.
79. Henry NL, Pchejetski D, A'Hern R, Nguyen A, Charles P, Waxman J, Li L, Storniolo A, Hayes DF, Flockhart DA, Stearns V, and Stebbing J. A Distinct Inflammatory Signature in Patients with Aromatase Inhibitor-Associated Musculoskeletal Syndrome. *British Journal of Cancer*. 2010, 103: 291-296.
80. Borges S, Desta Z, Jin Y, Faouzi A, Robarge JD, Philip S, Nguyen A, Stearns V, Hayes D, Rae JM, Skaar TC, Flockhart DA, and Li L. A composite functional genetic and co-medication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients. *Journal of Clinical Pharmacology*, 2010, 450-458.



81. **Li L**, Borges-Gonzales S, Robarge J, Sheng C, Desta Z, and Flockhart D. A Penalized mixture model approach in genotype/phenotype association analysis for quantitative phenotype. *Cancer Informatics*, 2010, 9: 93-103.
82. Wang Z, Kim S, Quinney SK, Zhou J, and **Li L**. Non-compartment model/compartment model transformation. *BMC System Biology*, 2010, 4(1): S8.
83. Friedman AN, Strother M, Quinney SK, Hall SD, Perkins SM, Brizendine EJ, Inman M, Gomez G, Shihabi Z, Moe S, and **Li L**. Measure the glomerular filtration rate in obese individuals without overt kidney disease. *Nephron Clinical Practice*, 2010, 116: 224-234.
84. Quinney SK, Zhang X, Lucksiri A, Gorski JC, **Li L**, and Hall SD. A Physiologically-Based Pharmacokinetic Model of Mechanism-Based Inhibition of CYP3A by Clarithromycin. *Drug Metabolism and Disposition*, 2010, 38: 241-248.
85. Atkinson EJ, McDonnell SK, Witte TS, Crawford DC, Fan Y, Fridley B, Li D, **Li L**, Rodin A, Sadee W, Speed T, Weiss ST, Yang J, Yerges L, and Schaid DJ. Lessons learned from the Fifth Statistical Analysis Workshop of the Pharmacogenetics Research Network. *The Pharmacogenetics Journal*, 2010, 11: 297-303.
86. Wang G, Wang Y, Teng M, Zhang D, **Li L**, and Liu Y. Signal transducers and activators of transcription-1 (STAT1) regulates microRNA transcription in Interferon gamma-stimulated HeLa cells. *PLoS One*, 2010, 5(7):e11794.
87. Wang G, Wang Y, Shen C, Huang Y, Huang K, Huang T, Nephew K, **Li L**, and Liu Y. RNA Polymerase II binding patterns reveal genomic regions involved in microRNA gene regulation. *PLoS One*, 2010, 5(11): e13798.
88. Fang F, Balch C, Schilder J, Breen T, Zhang S, Shen C, **Li L**, Kulesavage C, Snyder AJ, Nephew KP, and Matei DE. A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer. *Cancer*. 2010, 116 (17): 4043-4053.
89. Friedman AN, Yu Z, Juliar BE, Nguyen JT, Strother M, Quinney SK, **Li L**, Inman M, Gomez G, Shihabi Z, and Moe S. Independent influence of dietary protein on markers of kidney function and disease in obesity. *Kidney International*, 2010, 78: 693-697.
90. Hayes DF, Skaar TC, Rae JM, Henry NL, Nguyen AT, Stearns V, **Li L**, Philips S, Desta Z, and Flockhart DA. Estrogen receptor genotypes, menopausal status, and the effects of tamoxifen on lipid levels: revised and updated results. *The Journal of Clinical Pharmacology and Therapeutics*, 2010, 35: 626-629.
91. Wang X, Hickey R, Malkas L, Koch M, **Li L**, Zhang S, Sandusky GE, Grignon DJ, Eble JN, and Cheng L. Elevated expression of cancer-associated proliferating cell nuclear antigen in high-grade prostatic intraepithelial neoplasia and prostate cancer. *The Prostate*, 2010, 71: 748-754.
92. Jeong J, **Li L**, Liu Y, Nephew KP, Huang T, and Shen C. An empirical bayes model for gene expression and methylation profiles in antiestrogen resistant breast cancer. *BMC Biomedical Genetics*, 2010, 3: 55.
93. Egbelakin A, Ferguson MJ, MacGill EA, Lehmann AS, Topletz AR, Quinney SK, **Li L**, McCammack KC, Hall SD, Renbarger JL. Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia. *Pediatr Blood Cancer*. 2010; 56(3):361-7.

94. Zhou F, Zhao Q, Edenberg HJ, Goodlett CR, Liu Y, and Li L. Microarray and gene set enrichment analysis of differential gene expression upon alcohol exposure at early neurulation. *BMC Genomics*, 2011, 12:124.
95. Kim S and Li L. A novel global search algorithm for nonlinear mixed effect models using particle swarm optimization. *Journal of Pharmacokinetics and Pharmacodynamics*, 2011, 38: 471-495.
96. Shen C, Huang Y, Liu Y, Wang G, Zhao Y, Wang Z, Teng M, Wang Y, Flockhart DA, Skaar TC, Yan P, Nephew KP, Huang TH, and Li L. A modulated empirical bayes model for identifying topological and temporal estrogen receptor  $\alpha$  regulatory networks in breast cancer. *BMC Systems Biology*, 2011, 9; 5(1): 67.
97. Wessels AM, Flockhart DA, Carpenter JS, Radovich M, Li L, Miller KD, Sledge GW, Storniolo AM, Otte JL, Lemler SM, and Schneider BP. Cytochrome P450 polymorphisms and their relationship with premature ovarian failure in premenopausal women with breast cancer receiving doxorubicin and cyclophosphamide. *Breast Journal*, 2011, 17(5): 536-8.
98. Bell LN, Nguyen AT, Li L, Desta Z, Henry NL, Hayes DF, Wolff AC, Stearns V, Storniolo AM, and Flockhart DA. Comparison of changes in the lipid profile of postmenopausal women with early stage breast cancer treated with exemestane or letrozole. *The Journal of Clinical Pharmacology*, 2011, 52(12): 1852-1860.
99. Desta Z, Kreutz Y, Nguyen AT, Li L, Skaar T, Kamdem LK, Henry NL, Hayes DF, Storniolo AM, Stearns V, Hoffmann E, Tyndale RF, and Flockhart DA. Plasma letrozole concentrations in postmenopausal women with breast cancer are associated with CYP2A6 genetic variants, body mass index, and age. *Clinical Pharmacology & Therapeutics*, 2011, 90(5): 693-700.
100. Mitra R, Lee J, Jo J, Milani M, McClintick JN, Edenberg HJ, Kesler KA, Rieger KM, Badve S, Cummings OW, Mohiuddin A, Thomas DG, Luo X, Juliar BE, Li L, Mesaros C, Blair IA, Srirangam A, Kratzke RA, McDonald CJ, Kim J, and Potter DA. Prediction of postoperative recurrence-free survival in non-small cell lung cancer by using an internationally validated gene expression model. *Clinical Cancer Research*, 2011, 17(9): 2934-2946.
101. Hartmaier RJ, Richter AS, Gillihan RM, Sallit JZ, McGuire SE, Wang J, Lee AV, Osborne CK, O'Malley BW, Brown PH, Xu J, Skaar TC, Philips S, Rae JM, Azzouz F, Li L, Hayden J, Henry NL, Nguyen AT, Stearns V, Hayes DF, Flockhart DA, and Oesterreich S. A SNP in steroid receptor coactivator-1 disrupts a GSK3 $\beta$  phosphorylation site and is associated with altered tamoxifen response in bone. *Molecular Endocrinology*, 2012, 26(2): 220-227.
102. Kreutz RP, Nystrom P, Kreutz Y, Miao J, Desta Z, Breall JA, Li L, Chiang C, Kovacs R, Flockhart DA, and Jin Y. Influence of paraoxonase-1 Q192R and cytochrome P450 2C19 polymorphisms on clopidogrel response. *Clinical Pharmacology*, 2012, 4: 13-20.
103. Henry NL, Azzouz F, Desta Z, Li L, Nguyen AT, Lemler S, Hayden J, Tarpinian K, Yakim E, Flockhart DA, Stearns V, Hayes DF, and Storniolo AM. Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. *Journal of Clinical Oncology*, 2012, 30(9): 936-942.
104. Ramamoorthy A, Li L, Gaedigk A, Bradford LD, Benson EA, Flockhart DA, and Skaar TC. In silico and in vitro identification of microRNAs that regulate hepatic nuclear factor 4 $\alpha$  expression. *Drug Metabolism and Disposition*, 2012, 40(4): 726-733.
105. Haas DM, Lehmann AS, Skaar T, Philips S, McCormick CL, Beagle K, Hebring SJ, Dantzer J, Li L, and Jung J. The impact of drug metabolizing enzyme polymorphisms on outcomes after antenatal corticosteroid use. *American Journal of Obstetrics and Gynecology*, 2012, 206(5): 447.e17-e24.

106. Badve S, Goswami C, Polar Y, Nelson RP, Henley J, Miller N, Zaheer NA, Sledge GW. **Li L**, Kesler KA, Loehrer PJ. Molecular Analysis of Thymoma. *PLoS One*, 2012, 7, e42669.
107. Polar Y, Sanders KL, Goswami C, Cano OD, Zaheer NA, Jain RK, Kesler KA, Nelson RP, Vance GH, Smith D, Li L, Cardoso AA, Badve S, Loehrer PJ, and Sledge GW. Establishment and characterization of a novel cell line derived from human thymoma AB tumor. *Laboratory Investigation*, 2012, 92: 1564-10573.
108. Kim S and **Li L**. A switching Markov chain Monte Carlo method for statistical identifiability of nonlinear pharmacokinetics models. *Statistics in Sinica*, 2012, 22: 1199-1215.
109. Quinney SK, Mohammed AN, Herbert MF, Hass DM, Clark S, Umans JG, Caritis SN, and **Li L**. A semi-mechanistic metabolism model of CYP3A substrates in pregnancy: Predicting changes in midazolam and nifedipine pharmacokinetic. *CPT: Pharmacometrics and System Pharmacology*, 2012, 1(9): 1-9.
110. Teng M, Balch K, Liu Y, Huang T, Wang Y, Nephew K, and **Li L**. The influence of cis-regulatory elements on DNA methylation fidelity. *PLoS one*, 2012, 7(3): e32928.
111. Teng M, Wang Y, Kim S, **Li L**, Shen C, Liu Y, Huang T, Nephew KP, and Balch C. Empirical Bayes Model Comparisons for Differential Methylation Analysis. *Comparative and Functional Genomics*, 2012, 2012: 376706.
112. Duke J, Han X, Wang Z, Overhage M, Subhadarshini A, Karnik SD, Rocha LM, Li X, Strother M, Flockhart D, Quinney SK, and **Li L**. Literature based drug interaction discovery and its validation in the electronic medical record system. *PLoS Computational Biology*, 2012, 8(8): e1002614.
113. Zhang P, Mourad R, Xiang Y, Huang K, Huang T, Nephew K, Liu Y and **Li L**. A dynamic time order network for time-series gene expression data analysis. *BMC System Biology*, 2012, 6 (Suppl 3): S9.
114. Wu H, Zhang P, Nephew K, Huang T, Liu Y, **Li L**. A mediator based ER $\alpha$  regulatory network model of MCF7 cells. *BMC Genomics*, 2012, 13(Suppl 6): S6.
115. Zhou A, Breese MR, Hao Y, Edenberg HJ, **Li L**, Skaar TC, and Liu Y. Alt Event Finder: A tool for extracting alternative splicing events from RNA-seq data. *BMC Genomics*, 2012, 13(Suppl 8): S10.
116. Zhang J, Dhakal IB, Zhao Z, and **Li L**. Trend in mortality from cancers of the breast, colon, prostate, esophagus, and stomach in east Asia: role of nutrition transition. *European Journal of Cancer Prevention*, 2012, 21: 480-489.
117. Wei R, Yang F, Urban T, **Li L**, Chalasani N, Flockhart DA, and Liu W. Impact of the interaction between 3'-UTR SNPs and microRNA on the expression of human xenobiotic metabolism enzyme (XMEs) genes. *Frontiers in Pharmacogenetics and Pharmacogenomics*, 2012, 3: 120-128.
118. Kolchinsky A, Lourenço A, **Li L**, and Rocha LM. Evaluation of linear classifiers on articles containing pharmacokinetic evidence of drug-drug interactions. *Pacific Symposium Biocomputing*, 2013, 409-420.
119. Wu H, Karnik SD, Subhadarshini A, Wang Z, Philips S, Han X, Chiang C, Liu L, Boustani M, Rocha LM, Flockhart D, Quinney SK, and **Li L**. An Integrated Pharmacokinetics Ontology and Corpus for Text Mining. *BMC Bioinformatics*, 2013, 14:35.

120. Haas DM, Dantzer J, Lehmann AS, Philips S, Skaar TC, McCormick CL, Hebbing SJ, Jung J, and **Li L**. The impact of glucocorticoid polymorphisms on markers of neonatal respiratory disease after antenatal betamethasone administration. *American Journal of Obstetrics & Gynecology*, 2013, 208:215.e1-e6.
121. Schneider BP, Gray RJ, Radovich M, Shen F, Vance G, **Li L**, Jiang G, Miller KD, Gralow JR, Dickler MN, Cobleigh MA, Perez EA, Shenkier TN, Vang Nielsen K, Müller S, Thor A, Sledge GW Jr, Sparano JA, Davidson NE, and Badve SS. Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without Bevacizumab; Results from ECOG 2100 Trial. *Clinical Cancer Research*, 2013, 19(5): 1281-1289.
122. Unthank JL, McClintick JN, Labarrere CA, **Li L**, DiStasi MR, and Miller SJ. Molecular basis for impaired collateral artery growth in the spontaneously hypertensive rat: Insight from microarray analysis. *Physiology Reports*, 2013, 1(2): e0005.
123. Henry NL, Skaar TC, Dantzer J, **Li L**, Kidwell K, Gersch C, Nguyen AT, Rae JM, Desta Z, Oesterreich S, Philips S, Carpenter JS, Storniolo AM, Stearns V, Hayes DF, and Flockhart DA. Genetic associations with toxicity-related discontinuation of aromatase inhibitor therapy for breast cancer. *Breast Cancer Res Treat*, 2013, 138(3): 807-816.
124. Wang G, Qi K, Zhao Y, Li Y, Juan L, Teng M, **Li L**, Liu Y, and Wang Y. Identification of regulatory regions of bidirectional genes in cervical cancer. *BMC Medical Genomics*, 2013, 6 (Suppl 1): S5.
125. Quinney SK, Knopp S, Chang C, Hall SD and **Li L**. Integration of in vitro binding mechanism into the semi-physiologically based pharmacokinetic interaction model between ketoconazole and midazolam. *Pharmacometrics and System Pharmacology*, 2013, e75.
126. Xu C, Quinney SK, Guo Y, Hall SD, **Li L**, and Desta Z. CYP2B6 pharmacogenetics-based in vitro-in vivo extrapolation (IVIVE) of efavirenz clearance by PBPK modeling. *Drug Metabolism and Disposition*, 2013, 41(12): 2004-2011.
127. Chakraborty A, Jiang G, Boustani M, Skaar T, Liu Y, and **Li L**. Simultaneous inferences based on empirical Bayes methods and false discovery rates in eQTL data analysis. *BMC Genomics*, 2013, 14(Suppl 8): S8.
128. Jiang G, Chakraborty A, Wang Z, Boustani M, Liu Y, Skaar T, and **Li L**. New aQTL SNPs for the CYP2D6 Identified by a Novel Mediation Analysis of Genome-wide SNP Arrays, Gene Expression Arrays and CYP2D6 Activity. *Biomedical Research International*, 2013, 493019.
129. Ramamoorthy A, Liu Y, Philips S, Desta Z, Lin H, Goswami C, Gaedigk A, and **Li L**, Flockhart DA, and Skaar T. Regulation of miRNA expression by rifampin in human hepatocytes. *Drug Metabolism and Disposition*, 2013, 41(10): 1763-1768.
130. Campbell NL, Dexter P, Perkins AJ, Gao S, **Li L**, Skaar TC, Frame A, Hendrie HC, Callahan CM and Boustani MA. Medication adherence and tolerability of Alzheimer disease medications: study protocol for a randomized controlled trial. *Trials*, 2013, 14: 125.
131. Hsu PY, Hsu HK, Lan X, Juan L, Yan PS, Labanowska J, Heerema N, Hsiao TH, Chiu YC, Chen Y, Liu Y, **Li L**, Li R, Thompson IM, Nephew KP, Sharp ZD, Kirma NB, Jin VX, and Huang TH. Amplification of distant estrogen response elements deregulates target genes associated with tamoxifen resistance in breast cancer. *Cancer Cell*. 2013, 24(2): 197-212.

132. Vuppalanchi R, Liang T, Goswami CP, Nalamasu R, **Li L**, Jones D, Wei R, Liu W, Sarasani V, Janga SC, Chalasani N. Relationship between Differential Hepatic microRNA Expression and Decreased Hepatic Cytochrome P450 3A Activity in Cirrhosis. *PLoS ONE*, 2013, 8(9): e74471.
133. Kreutz RP, Owens J, Jin Y, Nystrom P, Desta Z, Kreutz Y, Breall JA, Li L, Chiang C, Kovacs RJ, Flockhart DA. Cytochrome P450 3A4\*22, PPAR- $\alpha$ , and ARNT polymorphisms and clopidogrel response. *Clinical Pharmacology : Advances and Applications*, 2013, 5:185-192.
134. Lavoie Smith EM, **Li L**, Hutchinson RJ, Ho R, Burnette WB, Wells E, Bridges C, Renbarger J. Measuring vincristine-induced peripheral neuropathy in children with acute lymphoblastic leukemia. *Cancer Nurs*. 2013;36(5):E49-60.
135. Schelleman H, Han X, Brensinger CM, Quinney SK, Bilker WB, Flockhart DA, **Li L**, and Hennessy S. Pharmacoepidemiologic and *in vitro* evaluation of potential drug-drug interactions of sulfonyleureas with fibrates and statins. *British Journal of Clinical Pharmacology*, 2014, 78(3): 639-648.
136. Kim S. and **Li L**. Statistical identifiability and convergence evaluation for nonlinear pharmacokinetic models with particle swarm optimization. *Computer Methods and Programs in Biomedicine*, 2014, 113 (2): 413-432.
137. Peng X, Wang F, **Li L**, Bum-Erdene K, Wang B, Pollok KE, Sandusky GE, Xu D, Turchi J, Jalal S, and Meroueh S. Exploring a structural protein-drug interactome for new therapeutics in lung cancer. *Molecular BioSystems*, 2014, 10: 581-591.
138. Hocevar BA, Kamendulis LM, Pu X, Perkins SM, Wang ZY, Johnston EL, DeWitt JM, **Li L**, Loehrer PJ, Klaunig JE, and Chiorean G. Contribution of environment and genetics to pancreatic cancer susceptibility. *PLoS One*, 2014, 9(3):e90052.
139. **Li L**. A horizon-prioritizing method can identify gaps among genomic application guidelines. *Clinical Pharmacology and Therapeutics*, 2014, 95: 368-369.
140. Wu HY, Chiang CW, **Li L**. Text mining for drug-drug interaction. *Methods Molecular Biology*, 2014, 1159: 47-75.
141. Gökmen-Polar Y, Goswami CP, Toroni RA, Sanders KL, Mehta R, Sirimalle U, Tanasa B, Shen C, **Li L**, Ivan S, Sledge Jr GW. Gene Expression Analysis Reveals Distinct Pathways of Resistance to Bevacizumab in Xenograft Models of Human ER-Positive Breast Cancer. *Journal of Cancer*, 2014, 5(8): 633-645.
142. Molosh AI, Johnson PL, Spence JP, Arendt D, Federici LM, Bernabe C, Janasik SP, Segu ZM, Khanna R, Goswami C, Zhu W, Park SJ, **Li L**, Mechref YS, Clapp DW, Shekhar A. Social learning and amygdala disruptions in Nf1 mice are rescued by blocking p21-activated kinase. *Nature Neuroscience*, 2014, 17(11): 1583-90.
143. Mourad R, Hsu PY, Juan L, She, C, Koneru P, Lin H, **Li L**. Estrogen induces global reorganization of chromatin structure in human breast cancer cells. *PLoS ONE*, 2014, 9(12): e113354.
144. Xiang Y, Albin A, Ren K, Zhang P, Etter JP, Lin S, **Li L**. Efficiently mining Adverse Event Reporting System for multiple drug interactions. *AMIA Summits on Translational Science Proceedings*, 2014, 120-125.
145. Bansal M, Yang J, Karan C, Li L, and NCI-DREAM consortium. Predictive activity of drug combinations through crowdsourcing. *Nature Biotechnology*, 2014, 32, 1213-22.

146. Schneider BP, **Li L**, Shen F, Miller KD, Radovich M, O'Neill A, Gray RJ, Lane D, Flockhart DA, Jiang G, Wang Z, Lai D, Koller D, Pratt JH, Dang CT, Northfelt D, Perez EA, Shenkier T, Cobleigh M, Smith ML, Railey E, Partridge A, Gralow J, Sparano J, Davidson NE, Foroud T, Sledge GW. Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100. *Br J Cancer*. 2014, 111,1241-8. (Li L. is the co-first author.)
147. Goswami C, Cheng L, Alexander PS, Singal A, and **Li L**. A new drug combinatory effect prediction algorithm on cancer cell based on gene expression and dose responsive curve. *Pharmacometrics and System Pharmacology*, 2015,4(2): e9.
148. Klochinsky A, Lourenco A, Wu HY, **Li L**, and Rocha LM. Extraction of pharmacokinetic evidence of drug-drug interactions from the literature. *PLoS One*, 2015,10(5): e0122199.
149. NL, Skaar TC, Perkins AJ, Gao S, **Li L**, Khan BA, Boustani MA. Characterization of hepatic enzyme activity in older adults with dementia: potential impact on personalizing pharmacotherapy. *Clinical Interventions Aging*, 2015, 10, 269-275.
150. Kim S, Gaweda AE, Wu D, **Li L**, Rai SN, Brier ME. Simplified Warfarin Dose-response Pharmacodynamic Models. *Biomedical engineering : applications, basis, and communications*. 2015, 27(1):1550001.
151. **Li L**. The potential of translational bioinformatics approaches for pharmacology research. *British Journal of Clinical Pharmacology*, 2015, 80(4):862-7.
152. Philips S., Zhou J., Li Z., Skaar T.C., and **Li L**. A translational bioinformatics approach in identifying and validating an interaction between vitamin A and CYP19A1. *BMC Genomics*, 2015, 16 Suppl 7:S17.
153. Wang L., Chang C., Liang H., Wu H., Feng W., Quinney S.K., Li J., **Li L**. How to choose in vitro systems to predict in vitro drug clearance: a system pharmacology prospective. *Biomed Res Int*. 2015, 2015.
154. Zhang P., Du L., Wang L., Liu M., Cheng L., Chiang C., Wu H., Quinney S.K., Li S., **Li L**. A mixture dose-response model for identifying high-dimensional drug interaction effects on myopathy using electronic medical record databases. *Pharmacometrics and System Pharmacology*, 2015, 4(8):474-80.
155. Du L., Chakraborty A., Zhang P., Chiang W., Cheng L., Quinney S.K., **Li L.**, and Li S. Graphic mining of high-order drug interactions and their directional effects on myopathy using electronic medical records. *Pharmacometrics and System Pharmacology*, 2015, 4(8):481-8. (Li L. is the co-corresponding author.)
156. Han X, Quinney SK, Wang Z, Zhang P, Desta Z, Elendorf J, Flockhart DA, and **Li L**. Simvastatin and loratadine interaction mechanisms and its increased myopathy risk. *Clinical Pharmacology and Therapeutics*. 2015, 98(3):321-7.
157. Schneider BP, **Li L**, Radovich M, Shen F, Miller KD, Flockhart DA, Jiang G, Vance G, Gardner L, Vatta M, Bai S, Lai D, Koller D, Zhao F, O'Neill A, Smith ML, Railey E, White C, Partridge A, Sparano J, Davidson NE, Foroud T, Sledge GW Jr. Genomic predictors for taxane-induced peripheral neuropathy in ECOG-5103 and ECOG-1199. *Clin Cancer Res*. 2015 15, 5082-91. (Li L is the co-first author.)
158. Lavoie Smith EM, **Li L**, Chiang C, Thomas K, Hutchinson RJ, Wells EM, Ho RH, Skiles J, Chakraborty A, Bridges CM, Renbarger J. Patterns and severity of vincristine-induced peripheral neuropathy in children with acute lymphoblastic leukemia. *J Peripher Nerv Syst*. 2015; 20(1):37-46.

159. Oesterreich S, Henry NL, Kidwell KM, Van Poznak CH, Skaar TC, Dantzer J, **Li L**, Hangartner TN, Peacock M, Nguyen AT, Rae JM, Desta Z, Philips S, Storniolo AM, Stearns V, Hayes DF, Flockhart DA. Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover. *Breast Cancer Res Treat.* 2015 Nov;154(2):263-73.
160. Cho DY, Shen JH, Lemler SM, Skaar TC, **Li L**, Bliedernicht J, Zanger UM, Kim KB, Shin JG, Flockhart DA, Desta Z. Rifampin enhances cytochrome P450 (CYP) 2B6-mediated efavirenz 8-hydroxylation in healthy volunteers. *Drug Metab Pharmacokinet.* 2016 Apr;31(2):107-16.
161. Zhang Y, Wu HY, Du J, Wang J, Tao C, **Li L**, Xu H. Extracting drug-enzyme relation from literature as evidence for drug drug interaction. *J Biomedical Semantics*, 2016, 7:11.
162. Alam K, **Pahwa S**, Wang X, Zhang P, Ding K, Abuznait AH, **Li L**, Yue W. Downregulation of Organic Anion Transporting Polypeptide (OATP) 1B1 Transport Function by Lysosomotropic Drug Chloroquine: Implication in OATP-Mediated Drug-Drug Interactions. *Mol Pharm*, 2016 Mar 7;13(3):839-51.
163. Cheng L, Schneider BP, **Li L**. A bioinformatics approach for precision medicine off-label drug drug selection among triple negative breast cancer patients. *J Am Med Inform Assoc.* 2016, 23, 741-9.
164. Han X, Chiang C, Leonard CE, Bilker WB, Brensinger CB, **Li L**, Hennessy S. Biomedical Informatics Approaches to Identifying Drug-Drug Interactions: Application to Insulin Secretagogues. *Clinical Pharmacology & Therapeutics.* 2016, 1;99:S99-100.
165. Hertz DL, Henry NL, Kidwell KM, Thomas D, Goddard A, Azzouz F, Speth K, **Li L**, Banerjee M, Thibert JN, Kleer CG, Stearns V, Hayes DF, Skaar TC, Rae JM. ESR1 and PGR polymorphisms are associated with estrogen and progesterone receptor expression in breast tumors. *Physiol Genomics.* 2016 Sep 1;48(9):688-98.
166. Hao Y, Zhang P, Xuei X, Nakshatri H, Edenberg HJ, **Li L**, Liu Y. Statistical modeling for sensitive detection of low-frequency single nucleotide variants. *BMC Genomics.* 2016 Aug 22;17 Suppl 7:514.
167. Huang K, Liu Y, Huang Y, **Li L**, Cooper L, Ruan J, Zhao Z. Intelligent biology and medicine in 2015: advancing interdisciplinary education, collaboration, and data science. *BMC Genomics.* 2016 Aug 22;17 Suppl 7:524.
168. Zhang Y, Wu H, Xu J, Wang J, Soysal E, Li L, Xu H. Leveraging syntactic and semantic graph kernels to extract pharmacokinetic drug drug interactions from biomedical literature. *BMC System Biology*, 2016, 26;10 Suppl 3:67 (co-corresponding author).
169. Cheng L, **Li L**. Systematic Quality Control Analysis of LINCS Data. *CPT Pharmacometrics and System Pharmacology*, 2016, 5(11): 588-98.
170. Schneider BP, Lai D, Shen F, Jiang G, Radovich M, **Li L**, Gardner L, Miller KD, O'Neill A, Sparano JA, Xue G, Foroud T, Sledge GW Jr. Charcot-Marie-Tooth gene, SBF2, associated with taxane-induced peripheral neuropathy in African-Americans. *Oncotarget*, 2016, 13:7(50): 82244-53.
171. Nebesio TD, Renbarger JL, Nabhan ZM, Ross SE, Slaven JE, **Li L**, Walvoord EC, Eugster EA. Differential effects of hydrocortisone, prednisone, and dexamethasone on hormonal and pharmacokinetic profiles: a pilot study in children with congenital adrenal hyperplasia. *Int J Pediatr Endocrinol*, 2016, 2016:17.

172. Carter J, Cheng L, Zucker J, Marshall M, Pollok K, Murray M, **Li L**, Renbarger J. Use of precision medicine molecular profiling of baseline tumor specimen may not benefit outcomes in children with relapsed, refractory, or rare pediatric sarcomas. *Clinical Pharmacology & Therapeutics*. 2016, doi: 10.1002/cpt.599.
173. Schneider BP, Shen F, Gardner L, Radovich M, **Li L**, Miller KD, Jiang G, Lai D, O'Neill A, Sparano JA, Davidson NE. Genome-Wide Association Study for Anthracycline-Induced Congestive Heart Failure. *Clinical Cancer Research*. 2017, 1;23(1):43-51.
174. Robarge JD, Desta Z, Nguyen AT, **Li L**, Hertz D, Rae JM, Hayes DF, Storniolo AM, Stearns V, Flockhart DA, Skaar TC. Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer. *Breast Cancer Research and Treatment*. 2016, 9:1-9.
175. Correia RB, **Li L**, Rocha LM. Monitoring potential drug interactions and reactions via network analysis of instagram user timelines. In Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing 2016 (Vol. 21, p. 492). NIH Public Access.
176. Jiang G, Fu Y, Li Z, Shirin A, Zhang P, Cheng L, **Li L**, and Chakraborty A. Expression quantitative locus mapping for identification of hotspots using an empirical Bayes mixture model. 2017 (in press).
177. Cheng L and **Li L**. The potentials of system pharmacology methods in predicting drug combinatory effects. *CPT Pharmacometrics and System Pharmacology*, 2017 (in press).

SERVICE  
Refereed

11/01/2016  
(Date)



(Signature of Candidate)